Home / News & Events / News / Bayer HealthCare and Peking University (PKU) Signs Comprehensive Colla...

Bayer HealthCare and Peking University (PKU) Signs Comprehensive Collaboration Agreement

January 8th, 2014 Bayer HealthCare and Peking University (PKU), Beijing, China, have signed a comprehensive collaboration agreement on a three-years strategic partnership to promote translational research for drug discovery. According to the agreement, the two partners will establish a joint research center at Peking University under the name Bayer HealthCare/Peking University Center of Translational Research for Drug Discovery (BPC/TRDD). Prof. Dr. Shiyi Chen, Vice Chancellor of Peking University, and Prof. Dr. Andreas Busch, Member of the Bayer HealthCare Executive Committee and Head of Global Drug Discovery attended the signing ceremony on January 8th, 2014, at the Peking University Boya International Conference Center.
Strategic alliances with international innovation partners from industry and academia are an essential element of our R&D strategy and complement our own research capabilities, said Prof. Dr. Andreas Busch. The establishment of this research collaboration with Peking University also demonstrates Bayers ongoing commitment to China as an important location in our innovation strategies. We are excited about the opportunity to collaborate with the excellent scientists at Peking University.

The collaboration will focus on applying basic research to drug discovery in the therapeutic areas of cardiology, oncology, hematology, and gynecological therapy, as well as technological research along the drug-discovery and -development value chain. Through this collaboration, scientists at PKU and BHC will be able to work together on the discovery of new medicines and contribute to the innovation landscape in China.

The open innovation model chosen for this industry/university partnership is an excellent way to combine the academic creativity at Peking University with Bayer HealthCares industrial drug development experience to accelerate todays drug-discovery processes, said Prof. Dongmin Chen, Dean of the School of Innovation and Entrepreneurship and Director of the Office of Science and Technology Development at Peking University.

The Bayer HealthCare/Peking University Center of Translational Research for Drug Discovery will serve as a platform enabling scientists in life-sciences-related schools such as the School of Life Sciences & Institute of Molecular Medicine and the School of Chemical Biology & Biotechnology and other affiliations at Peking University - to collaborate with scientists at Bayer HealthCare Global Drug Discovery. 

The broad spectrum of basic research expertise at PKU perfectly complements Bayers experience and long-term commitment in novel drug discovery, said Prof. Hong Wu, Dean of the School of Life Sciences of Peking University and a Fellow of the American Association for the Advancement of Science, who will serve as the co-director from PKU side and work with Dr. Jennifer Hu, the co-director from Bayer side, to overs the research activities at the BPC/TRDD. We are looking forward to collaborating with our colleagues at Bayer to improve human health through translational research.

As part of the agreement with Peking University, Bayer HealthCare will provide funding for collaborative research projects. In addition, Bayer will sponsor a Bayer Professorship and Bayer Investigator Awards to promote and reward scientific excellence, important contributions to life sciences, and research that is beneficial to drug discovery, especially in the fields of Bayer HealthCares core therapeutic areas. 

The strategic partnership with Peking University further underlines Bayer HealthCares ongoing commitment to China as an important location in its innovation strategy. Bayer HealthCares Innovation Center China was established as early as 2009 as part of its R&D Center China to strengthen the companys global research-and-development capabilities and to include the clinical profiles and medical needs of Asian patients early on in its drug development activities.
About Peking University :

Peking University (PKU) is the first national comprehensive university in China, established in 1898. It has become one of the top comprehensive national key universities in China, consisting of 41 schools with disciplines in natural sciences, humanities, social sciences, technological sciences, information science & engineering, medical sciences, etc. Currently, there are more than 8,600 faculty and staff members, over 30,000 undergraduate and graduate students, and over 271 institutes and research centers at Peking University. Some of its strong disciplines relevant to drug discovery include life sciences, chemistry, medical and pharmaceutical sciences, as well as 8 affiliated hospitals. Nowadays, Peking University has become the cradle for high-caliber and creative talents, a frontier of research and innovation, as well as a bridge for international exchanges in China. In the past few years, it has hosted the visits of the government heads of nearly 30 countries and states and nearly 300 chancellors of world-renown universities. It has established exchange programs with more than 240 universities from over 50 countries. 
About Bayer HealthCare :

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the worlds leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCares aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 54,900 employees (Dec 31, 2012) and is represented in more than 100 countries. More information at www.healthcare.bayer.com.